Edesa Biotech Inc Stock
Edesa Biotech Inc Stock
Pros and Cons of Edesa Biotech Inc in the next few years
Pros
Cons
Performance of Edesa Biotech Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Edesa Biotech Inc | - | - | - | - | - | - | - |
| AEterna Zentaris Inc. | -0.540% | 0.000% | -1.182% | -34.867% | 5.384% | -90.479% | -98.034% |
| Satellos Bioscience Inc. | -1.240% | -3.593% | -1.829% | -9.040% | 16.667% | -74.844% | - |
| Burcon Nutrascience Corp. | -3.730% | -10.876% | -21.123% | -16.193% | 10.902% | -95.496% | -24.745% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, the financials of Edesa Biotech (EDSA) from the Biotechnology & Medical Research industry seem to present a mixed picture. The company is engaged in extensive research and development, which is a positive indication of its focus on innovation. However, several concerning aspects must be carefully considered in terms of its financial health.
Research and Development Expenses: Edesa Biotech has consistently invested in research and development, which is essential for biotechnology companies to discover and develop breakthrough products. From 2020 to 2022, the research and development expenses have consistently increased, indicating a dedication to innovation that may pay off in the long term.
Current Ratio: EDSA maintains a healthy current ratio in recent years, indicating adequate liquidity to meet short-term obligations. In 2021, the current ratio was 8.32, while in 2022 the ratio was 4.25. This suggests financial stability and good cash management in the short term.
Comments